ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM
Abstract Number: 0412
2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris
9:00AM-11:00AM
Abstract Number: 0407
Achievement of Early and Sustained Complete Response of Oral Ulcers with Apremilast Compared with Placebo in Patients with Active Behçet’s Syndrome
9:00AM-11:00AM
Abstract Number: 0424
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0415
Characteristics of Arthritis in Adult IgA Vasculitis
9:00AM-11:00AM
Abstract Number: 0414
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
9:00AM-11:00AM
Abstract Number: 0409
Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size
9:00AM-11:00AM
Abstract Number: 0403
Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
9:00AM-11:00AM
Abstract Number: 0413
Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature
9:00AM-11:00AM
Abstract Number: 0423
Defining Ear Chondritis: Data from 685 Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0417
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
9:00AM-11:00AM
Abstract Number: 0405
Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment
9:00AM-11:00AM
Abstract Number: 0428
Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis
9:00AM-11:00AM
Abstract Number: 0408
Epidemiology and Treatment of Behçet’s Disease Insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry
9:00AM-11:00AM
Abstract Number: 0410
Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis
9:00AM-11:00AM
Abstract Number: 0422
Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0416
IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort
9:00AM-11:00AM
Abstract Number: 0406
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
9:00AM-11:00AM
Abstract Number: 0404
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
9:00AM-11:00AM
Abstract Number: 0425
MAGIC Syndrome in a Cohort of Patients with Relapsing Polychondritis
9:00AM-11:00AM
Abstract Number: 0421
Polymyalgia Rheumatica Is Associated with Later Menopause: An Observational Study
9:00AM-11:00AM
Abstract Number: 0418
Prevalence of Thyroid Disease Among Patients with Vasculitis
9:00AM-11:00AM
Abstract Number: 0420
Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0411
Serial Vessel Wall Enhancement Change on High-Resolution MRI Vessel Wall Imaging in Primary Central Nervous System Vasculitis
9:00AM-11:00AM
Abstract Number: 0419
Survival and Prevalent Comorbidities in Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 0426
T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP)
9:00AM-11:00AM
Abstract Number: 0427
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology